Shanghai-based endocrine therapy developer VISEN Pharmaceuticals has raised an aggregate of $150 million in its Series B round to facilitate its development in the Greater China region.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
